Vigil Neuroscience, Inc.
VIGL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.29 | 1.14 | -0.15 | -0.14 |
| FCF Yield | -74.10% | -54.29% | -16.68% | -11.39% |
| EV / EBITDA | -0.51 | -1.05 | -3.05 | -6.06 |
| Quality | ||||
| ROIC | -106.03% | -68.30% | -36.06% | -44.94% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.61 | 0.85 | 0.95 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 27.89% | -7.52% | -67.05% | -596.32% |
| Safety | ||||
| Net Debt / EBITDA | 0.31 | 0.43 | 2.71 | 2.13 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.10 | 0.00 |
| Cash Conversion Cycle | -1,584.89 | -1,780.18 | 3,113.34 | -4,207.55 |